Maxillary Antral Sinus Washout — Cost, Top Hospitals & Success Rates | MyMedicPlus

Maxillary antral sinus washout (antral lavage or antral puncture and irrigation) is an ENT procedure in which the maxillary sinus (antrum) is accessed with a needle or cannula and irrigated with saline to flush out inspissated secretions, pus, and debris. It serves both a diagnostic function (recovery of material for microbiological culture to identify causative organisms and guide antibiotic therapy) and a therapeutic function (physical removal of viscous inflammatory secretions that cannot drain via the natural ostium).

The classical access route is through the inferior meatus of the nasal cavity, using a Lichtwitz antral cannula — a curved metal trocar and cannula system that punctures the thin medial wall of the maxillary sinus (the lateral wall of the inferior meatus) with minimal force. The sinus is then irrigated with normal saline until the return fluid runs clear. Recovered purulent washings are sent for Gram stain, aerobic and anaerobic culture, and sensitivity testing.

Historically, antral washout was one of the most commonly performed ENT procedures for recurrent acute and chronic maxillary sinusitis. Its role has evolved considerably with the EPOS 2020 guidelines (European Position Paper on Rhinosinusitis and Nasal Polyps), which now position functional endoscopic sinus surgery (FESS) with middle meatal antrostomy as the preferred surgical intervention for chronic rhinosinusitis (CRS) after failure of medical therapy, because FESS restores physiological mucociliary drainage through the natural ostium and allows direct endoscopic visualisation and access for topical therapy.

Maxillary antral sinus washout may be indicated in the following clinical contexts:

• Acute maxillary sinusitis with purulent opacification: When clinical and radiological (CT sinus) evidence of purulent maxillary sinusitis is present and empirical antibiotic therapy has failed or a specific organism is required for targeted therapy — particularly in immunocompromised patients, nosocomial sinusitis (ICU patients with nasogastric or nasotracheal tubes), or suspected resistant organisms.
• Chronic rhinosinusitis (CRS) without nasal polyps: Defined by EPOS 2020 as nasal symptoms (blockage, discharge, facial pain/pressure, or hyposmia) persisting for >12 weeks with objective evidence of sinus mucosal thickening or opacification on CT or endoscopy. Antral washout may provide temporary symptomatic relief and diagnostic material when FESS is awaited or not yet planned.
• Chronic rhinosinusitis with nasal polyps (CRSwNP): Less of a primary indication; FESS and biologic therapy (dupilumab, mepolizumab) are preferred for CRSwNP, but washout may be performed at the time of diagnostic evaluation.
• Diagnostic purpose in immunocompromised patients: In neutropenic patients, diabetics, or those on immunosuppressive therapy with acute sinusitis, washout provides material for fungal culture (invasive aspergillosis, mucormycosis) where targeted antifungal therapy is life-saving. Sinus endoscopy with biopsy is preferred when invasive fungal sinusitis is suspected, but washout may complement assessment.
• Dental sinusitis (odontogenic sinusitis): Maxillary sinusitis secondary to periapical dental pathology or displaced dental implants; washout for culture, combined with dental extraction/treatment and nasal antrostomy.
• Barotraumatic sinusitis: In aircrew or divers with acute barotraumatic sinus haemorrhage causing antral haematoma, washout may facilitate drainage and recovery.

• Appropriate candidates: Adults and older children with acute or chronic maxillary sinusitis unresponsive to medical management (antibiotics, saline irrigation, intranasal corticosteroids), with CT or clinical evidence of maxillary sinus opacification, who either: require microbiological identification of the causative organism; or need symptomatic relief pending more definitive surgical management (FESS).
• Diagnostic indication in ICU sinusitis: Patients with nosocomial sinusitis in intensive care (long-term nasogastric intubation causes mucosal oedema, impairs drainage, and promotes sinus infection with hospital-acquired organisms — often gram-negative rods, MRSA, or fungi); culture from antral washout guides targeted antibiotic therapy.
• Contraindications:
  • Known coagulopathy or therapeutic anticoagulation (relative — requires haematology advice; risk of significant epistaxis).
  • Very young children — inferior meatus is anatomically too small; FESS under general anaesthesia is preferred.
  • Hypoplastic or absent maxillary sinus (rare anatomical variant).
  • Recent maxillary sinus surgery (risk of damage to surgical reconstruction).
  • Allergy to local anaesthetics used (cocaine or lidocaine for topical preparation).
• Patient factors: Procedure is well-tolerated under local anaesthesia in compliant adults; anxious or needle-phobic patients may prefer general anaesthesia or the procedure combined with FESS.

1. Preparation and Anaesthesia
The patient is seated upright. The nasal cavity is prepared with:

• Topical vasoconstrictor: Co-phenylcaine spray (5% cocaine with 1:2000 phenylephrine) or xylometazoline (0.1%) spray to decongest the nasal mucosa, shrink the inferior turbinate, and widen the inferior meatus, improving both access and anaesthesia.
• Topical anaesthesia: Pledgets soaked in 4–5% lidocaine are placed in the inferior meatus against the lateral nasal wall for 5–10 minutes. Local infiltration with 1–2% lidocaine and 1:80,000 adrenaline along the inferior meatus wall may supplement topical anaesthesia.
• No systemic sedation is usually required for cooperative adults.

2. Lichtwitz Cannula Puncture
The Lichtwitz antral cannula is a curved metal trocar-and-cannula system. The trocar is placed with its curve pointing laterally and superiorly into the inferior meatus, approximately 1.5–2 cm posterior to the anterior end of the inferior turbinate. The thin bone of the medial maxillary sinus wall (the fontanelle region) is punctured with a short, controlled rotational motion — a characteristic 'give' is felt as the cannula enters the sinus. The trocar is removed, leaving the cannula in position in the sinus.

Critical safety point: Air is never used for irrigation — air insufflation into the maxillary sinus carries a risk of fatal air embolism if air enters a venous sinus or vessel, particularly through inflamed mucosa with compromised vascular integrity. Only saline is used.

3. Aspiration and Culture
Before irrigation, the syringe is first used to gently aspirate any pus or fluid present in the sinus — this undiluted material is the optimal sample for microbiological culture (aerobic, anaerobic, fungal), Gram stain, and cytology. The sample is sent in a sealed syringe or culture transport medium to the microbiology laboratory immediately.

4. Saline Irrigation (Washout)
Warm normal saline (0.9% NaCl) is then gently irrigated into the sinus through the cannula. A second nasal tube or the natural ostium (which opens into the middle meatus medially) allows washings to drain into the nasopharynx and be expectorated or collected. Irrigation continues until the return fluid is clear. Typically 50–100 mL of saline is used. The patient is asked to lean forward with the mouth open to allow drainage. Forceful irrigation is avoided as it may force infected material through the natural ostium retrogradely into surrounding tissues.

5. Post-Procedure
The cannula is removed with gentle pressure to the puncture site. Light epistaxis is common and settles spontaneously. The patient observes in clinic for 15–30 minutes. Post-procedural saline nasal douching (douching twice daily) is recommended to maintain drainage.

Microbiological Culture Guidance
Antral culture results typically return within 48–72 hours. Common pathogens in community-acquired CRS include: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (in acute sinusitis); Staphylococcus aureus and anaerobes (Peptostreptococcus, Prevotella) in chronic sinusitis; gram-negative rods (Pseudomonas aeruginosa, Klebsiella) in ICU sinusitis. Culture-directed antibiotic therapy significantly improves cure rates compared to empirical broad-spectrum antibiotics alone.

• Diagnostic precision: Antral washout provides a direct culture specimen from the sinus, bypassing nasal surface flora contamination. This enables targeted antibiotic therapy based on culture and sensitivity, avoiding unnecessary broad-spectrum antibiotic use and reducing antibiotic resistance.
• Immediate symptomatic relief: Physical removal of inspissated pus and secretions relieves sinus pressure, facial pain, and nasal congestion — often providing faster symptomatic benefit than antibiotics alone.
• Minimally invasive, day-case procedure: Performed under local anaesthesia in the outpatient ENT clinic or minor procedure room; no general anaesthesia required in adults; minimal recovery time.
• Avoids immediate surgery: In patients with acute sinusitis or early chronic disease, antral washout may provide sufficient therapeutic benefit to defer or avoid FESS, which carries greater procedural risks.
• Critical in immunocompromised patients: Early identification of fungal organisms (Aspergillus, Mucor) via antral washings can be life-saving in immunocompromised patients where invasive fungal sinusitis may spread rapidly to the orbit, skull base, and brain.

• Infra-orbital nerve paraesthesia: The infra-orbital nerve exits the maxillary bone through the infra-orbital foramen just above the anterior maxillary sinus wall. Inadvertent contact or injection near this structure during LA infiltration causes numbness over the ipsilateral cheek, upper lip, and side of the nose — almost always transient, resolving within hours to days as local anaesthetic wears off. Permanent damage is extremely rare with correct technique.
• Epistaxis: Mild bleeding at the puncture site from the nasal mucosa is common and almost always self-limiting. Significant epistaxis requiring nasal packing or intervention is rare (<1%). Increased risk in patients on anticoagulants or with bleeding disorders.
• Orbital entry (orbital penetration): If the cannula is directed superolaterally rather than laterally into the inferior meatus, it may penetrate the orbital floor — a rare but serious complication. Presents as sudden onset periorbital pain, proptosis, and potential visual disturbance. Risk is minimised by proper technique (keeping the cannula trajectory horizontal and lateral) and familiarity with anatomical landmarks. If orbital entry is suspected, the cannula is immediately removed and ophthalmological assessment is obtained.
• Air embolism: A historically recognised but preventable complication. Occurs if air is introduced into the sinus and enters a venous sinus or dilated vessel through inflamed mucosa — potentially fatal. Prevented absolutely by never using air for irrigation — only saline is used. Modern technique guidelines and training explicitly prohibit air insufflation.
• Cheek or facial soft tissue emphysema: Air forced via a perforated sinus wall or access port into the subcutaneous tissues of the face — avoided by the exclusive use of saline.
• Failure to access sinus (failed puncture): In patients with a very thick inferior meatus wall (uncommon anatomical variant), a very small sinus, or prior surgery, the Lichtwitz cannula may not gain entry — alternative access via the canine fossa (anterior wall) or surgical FESS is then required.
• Incomplete drainage: Thick, mucoid, or fungal secretions may not be fully flushed by simple saline irrigation, limiting the therapeutic benefit. FESS with direct visualisation provides more reliable clearance.

Post-procedure management is directed by the clinical indication and culture results:

• Culture-directed antibiotic therapy: Sensitivity results from antral washings guide switch to the narrowest-spectrum effective antibiotic. For acute sinusitis confirmed on culture, a 7–14 day course of the appropriate antibiotic is prescribed. For chronic sinusitis with biofilm-forming organisms (e.g., Pseudomonas), longer courses or topical antibiotics may be used.
• Intranasal corticosteroid therapy: Continued or initiated post-washout (e.g., mometasone 200 mcg daily, fluticasone 200 mcg daily) to reduce mucosal oedema and prevent recurrence. EPOS 2020 recommends intranasal steroids as first-line maintenance therapy for all forms of CRS.
• Saline nasal douching: High-volume saline irrigation (240 mL twice daily with a Neti pot or squeeze bottle) promotes drainage, clears residual debris, and maintains mucociliary function. Isotonic or hypertonic (1.8%) saline may be used.
• Follow-up at 4–6 weeks: Clinical review to assess symptomatic response, review culture results, and evaluate for need for FESS. Flexible nasal endoscopy to assess middle meatus for persistent disease, polyps, or mucosal oedema.
• CT sinus review: Repeat CT sinuses at 8–12 weeks if symptoms persist, to quantify disease burden (Lund-Mackay CT score) and guide surgical planning for FESS.
• FESS planning: If symptoms persist despite medical therapy and antral washout, referral for FESS with middle meatal antrostomy is recommended per EPOS 2020 guidelines. FESS provides superior long-term disease control and is the preferred definitive surgical intervention for CRS.

Antral washout is one of the most cost-effective ENT procedures available:

• Outpatient antral washout under LA (private clinic, India): USD 30–150 inclusive of procedure and culture processing — one of the lowest-cost diagnostic sinus procedures.
• Antral washout in NHS (UK): Available as an outpatient ENT procedure; NHS tariff approximately GBP 200–400 as a daycase procedure.
• Antral washout under GA (day surgery, India): USD 200–600 inclusive of day-surgery facility and anaesthesia.
• Microbiological culture and sensitivity testing: USD 20–80 in India; GBP 50–100 in the UK. A key component of the diagnostic value of the procedure.
• FESS (functional endoscopic sinus surgery) — for comparison: USD 500–2,000 in India (government hospitals); USD 2,000–6,000 in private Indian hospitals; USD 10,000–25,000 in the United States. FESS is a single, more definitive procedure that often eliminates the need for repeat antral washouts.
• Balloon sinuplasty — for comparison: USD 2,000–5,000 in India; USD 4,000–12,000 in the United States. Less tissue-destructive than FESS; suitable for uncomplicated CRS without polyps.
• Overall cost of CRS management: EPOS 2020 recommends a step-up approach — intranasal steroids and saline irrigation first; short-course oral steroids and antibiotics second; sinus surgery (FESS) for failures. Antral washout with culture guidance avoids inappropriate antibiotic therapy, reducing drug costs and resistance.

• FESS — Functional Endoscopic Sinus Surgery with Middle Meatal Antrostomy: The current gold-standard surgical treatment for CRS. Under general anaesthesia, a rigid endoscope is introduced into the nasal cavity; the natural maxillary sinus ostium (in the middle meatus) is widened (antrostomy), diseased mucosa and polyps are removed, and the frontal and ethmoid sinuses may also be opened (pan-sinus surgery). This restores natural mucociliary drainage pathways, allows topical drug delivery directly into the sinuses (steroid drops/irrigations), and enables post-operative endoscopic surveillance and debridement. EPOS 2020 recommends FESS as the surgical treatment of choice when medical therapy fails. Antral washout cannot replicate these benefits as it does not address the natural drainage pathway.
• Balloon sinuplasty (BSP): A catheter-based technique using a flexible balloon to dilate the natural sinus ostia without tissue removal. Suitable for uncomplicated CRS without large polyps; performed under local or general anaesthesia; recovery is faster than FESS. Less effective for CRS with polyps or in patients requiring tissue removal. The REMODEL trial demonstrated similar symptom improvement to FESS in uncomplicated CRS at 2 years.
• Canine fossa puncture: Alternative access route for antral washout through the anterior wall of the maxillary sinus in the canine fossa (above the upper canine tooth), under infiltration LA. Useful when inferior meatal access fails (very small inferior meatus, prior inferior meatal antrostomy). Requires mucosal incision in the gingivobuccal sulcus.
• High-volume nasal saline irrigation (Neti pot / Neil Med squeeze bottle): Non-invasive saline irrigation performed at home by the patient twice daily. Strong evidence base (EPOS 2020 Grade A recommendation) for symptomatic benefit in CRS as first-line treatment. Reduces mucosal oedema, promotes mucociliary clearance, and is inexpensive. Should be offered to all CRS patients before invasive procedures.
• Intranasal corticosteroid therapy: Recommended as the cornerstone of CRS medical management (EPOS 2020). Mometasone furoate, fluticasone propionate, budesonide — all reduce mucosal oedema, polyp size (in CRSwNP), and symptom burden. Many CRS patients achieve satisfactory control with corticosteroids + saline douching without requiring antral washout or surgery.
• Biologic therapy for CRSwNP: Dupilumab (anti-IL-4/13), mepolizumab (anti-IL-5), and omalizumab (anti-IgE) are approved for severe refractory CRS with nasal polyps. These target the type 2 inflammatory pathway driving most CRSwNP. They reduce polyp burden, restore smell, and may defer the need for surgery — but are expensive (USD 15,000–40,000/year) and require specialist prescribing.